Hillary J. Millar

1.1k total citations
14 papers, 773 citations indexed

About

Hillary J. Millar is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hillary J. Millar has authored 14 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hillary J. Millar's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Signaling Pathways in Disease (2 papers) and Peptidase Inhibition and Analysis (2 papers). Hillary J. Millar is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Signaling Pathways in Disease (2 papers) and Peptidase Inhibition and Analysis (2 papers). Hillary J. Millar collaborates with scholars based in United States, Netherlands and Belgium. Hillary J. Millar's co-authors include Francis L. McCabe, Marian T. Nakada, Peter J. Bugelski, Yan Li, Patricia Rafferty, Prabakaran Kesavan, Yi Tang, Geoffrey M. Anderson, Linda A. Snyder and Sylvie Laquerre and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Hillary J. Millar

14 papers receiving 760 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hillary J. Millar United States 9 483 356 246 150 96 14 773
Kalyan C. Nannuru United States 16 376 0.8× 494 1.4× 274 1.1× 190 1.3× 95 1.0× 20 886
Jay Overholser United States 11 439 0.9× 358 1.0× 186 0.8× 157 1.0× 117 1.2× 16 767
Carolina Zandueta Spain 17 443 0.9× 305 0.9× 119 0.5× 281 1.9× 168 1.8× 25 833
Tetsuji Sawada Japan 20 494 1.0× 392 1.1× 220 0.9× 199 1.3× 138 1.4× 38 928
Carmine Fedele United States 12 628 1.3× 280 0.8× 148 0.6× 214 1.4× 142 1.5× 16 870
Jessica C.A. Bouma-ter Steege Netherlands 8 410 0.8× 322 0.9× 339 1.4× 142 0.9× 57 0.6× 9 851
Nadja Zaborsky Austria 18 283 0.6× 336 0.9× 386 1.6× 93 0.6× 42 0.4× 49 945
Karmele Valencia Spain 16 445 0.9× 265 0.7× 106 0.4× 310 2.1× 154 1.6× 29 775
D. Fan United States 14 404 0.8× 359 1.0× 97 0.4× 119 0.8× 168 1.8× 23 804
Beáta Somlai Hungary 14 289 0.6× 568 1.6× 567 2.3× 94 0.6× 52 0.5× 29 934

Countries citing papers authored by Hillary J. Millar

Since Specialization
Citations

This map shows the geographic impact of Hillary J. Millar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hillary J. Millar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hillary J. Millar more than expected).

Fields of papers citing papers by Hillary J. Millar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hillary J. Millar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hillary J. Millar. The network helps show where Hillary J. Millar may publish in the future.

Co-authorship network of co-authors of Hillary J. Millar

This figure shows the co-authorship network connecting the top 25 collaborators of Hillary J. Millar. A scholar is included among the top collaborators of Hillary J. Millar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hillary J. Millar. Hillary J. Millar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Carton, Jill M., Hillary J. Millar, David H. Walker, et al.. (2024). A Novel, Universal Targeting Receptor-Adaptor CAR Platform Demonstrates Versatile, Flexible, and Controlled Tumor Inhibition in an Ipsc-Derived T-Cell. Blood. 144(Supplement 1). 7181–7181. 1 indexed citations
2.
Millar, Hillary J., David H. Walker, Liam Campion, et al.. (2024). Abstract 6802: CXCR4 transgene improves in vivo migration and efficacy of engineered iPSC-derived natural killer cells. Cancer Research. 84(6_Supplement). 6802–6802. 2 indexed citations
3.
Vijayaraghavan, Smruthi, Lorraine Lipfert, Kristen Chevalier, et al.. (2020). Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Molecular Cancer Therapeutics. 19(10). 2044–2056. 138 indexed citations
4.
Millar, Hillary J., Dirk Brehmer, Tinne Verhulst, et al.. (2019). Abstract 950: In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models. Cancer Research. 79(13_Supplement). 950–950. 8 indexed citations
5.
Wu, Tongfei, Hillary J. Millar, Dana Gaffney, et al.. (2018). Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models. Cancer Research. 78(13_Supplement). 4859–4859. 21 indexed citations
6.
Millar, Hillary J., Jeffrey A. Nemeth, Francis L. McCabe, Bill Pikounis, & Eric Wickstrom. (2008). Circulating Human Interleukin-8 as an Indicator of Cancer Progression in a Nude Rat Orthotopic Human Non–Small Cell Lung Carcinoma Model. Cancer Epidemiology Biomarkers & Prevention. 17(8). 2180–2187. 20 indexed citations
7.
Snyder, Linda A., Prabakaran Kesavan, Frank McCabe, et al.. (2007). Neutralization of CCL2 inhibits tumor angiogenesis and pancreatic tumor growth. Molecular Cancer Therapeutics. 6. 4 indexed citations
8.
Chen, Qiming, Carol D. Manning, Hillary J. Millar, et al.. (2007). CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clinical & Experimental Metastasis. 25(2). 139–148. 77 indexed citations
9.
Chen, Qiming, Hillary J. Millar, Francis L. McCabe, et al.. (2007). αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models. Clinical Cancer Research. 13(12). 3689–3695. 22 indexed citations
10.
Picha, Kristen, Francis L. McCabe, Hillary J. Millar, et al.. (2006). CNTO 859, a humanized anti‐tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. International Journal of Cancer. 120(6). 1261–1267. 68 indexed citations
11.
Tang, Yi, Marian T. Nakada, Patricia Rafferty, et al.. (2006). Regulation of Vascular Endothelial Growth Factor Expression by EMMPRIN via the PI3K-Akt Signaling Pathway. Molecular Cancer Research. 4(6). 371–377. 111 indexed citations
12.
Tang, Yi, Marian T. Nakada, Prabakaran Kesavan, et al.. (2005). Extracellular Matrix Metalloproteinase Inducer Stimulates Tumor Angiogenesis by Elevating Vascular Endothelial Cell Growth Factor and Matrix Metalloproteinases. Cancer Research. 65(8). 3193–3199. 297 indexed citations
13.
Kesavan, Prabakaran, Francis L. McCabe, Hillary J. Millar, et al.. (2005). Anti-CCL-2 / MCP-1 (monocyte chemoattractant protein-1) monoclonal antibodies effectively inhibit tumor angiogenesis and growth of human breast carcinoma. Cancer Research. 65. 254–254. 3 indexed citations
14.
Scallon, Bernie, Richard Tawadros, Frank McCabe, et al.. (2004). Enhanced Tumor Inhibition of MDA-MB-231 Breast Carcinoma by the Anti-Tissue Factor Antibody, CNTO 860, Is Mediated by Antibody Dependent Cellular Cytotoxicity. Journal of Immunotherapy. 27(6). S10–S10. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kalyan C. Nannuru Breakdown of academic impact, for papers by Jay Overholser Breakdown of academic impact, for papers by Carolina Zandueta Breakdown of academic impact, for papers by Tetsuji Sawada Breakdown of academic impact, for papers by Carmine Fedele Breakdown of academic impact, for papers by Jessica C.A. Bouma-ter Steege Breakdown of academic impact, for papers by Nadja Zaborsky Breakdown of academic impact, for papers by Karmele Valencia Breakdown of academic impact, for papers by D. Fan Breakdown of academic impact, for papers by Beáta Somlai
Rankless by CCL
2026